Noble Financial Remains Netural on Galena's (GALE) Legal Issues; Maintains 'Buy' Rating
Tweet Send to a Friend
Noble Financial maintains Galena Biopharma (Nasdaq: GALE) at Buy with a price target of $6.
Analyst Rahul Jasuja noted ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Analyst Rahul Jasuja noted ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
